61-Patient Study: Elevated Blood Microplastics Linked to Heart Attack Risk

A groundbreaking cross-sectional study conducted by Italian researchers has found that patients who suffered an acute heart attack (myocardial infarction) have significantly higher levels of micro- and nanoplastics (MNPs) in their blood compared to individuals with chronic ischemic heart disease or normal coronary arteries. Published on July 14–15, 2026, and reported by GEN and News-Medical, this 61-patient investigation marks the first direct association between circulating plastic particle concentrations and a major acute cardiovascular event, moving beyond prior detections of MNPs in human tissues to a clinically relevant endpoint. The study, led by teams at Sapienza University of Rome, University of Verona, and University of Campania “Luigi Vanvitelli,” enrolled patients at two Italian hospitals: Sant’Andrea University Hospital in Rome and Azienda Ospedaliera Universitaria Integrata of Verona. Participants were categorized by angiography into three groups: acute heart attack, chronic ischemic heart disease, or normal coronary supply. The results revealed a clear gradient, with the highest MNP levels measured in the heart attack cohort. Investigators also found that smoking history and exposure to high air pollution were independently associated with elevated blood MNPs, suggesting that pulmonary damage might facilitate the systemic entry of these ubiquitous environmental particles. Emanuele Barbato, MD, PhD, lead researcher at Sapienza University, cautioned that the study does not prove causation but underscores a strong environmental link. Cardiovascular disease is increasingly viewed as a condition influenced by lifelong environmental exposures, and plastic pollution—now measured in the human bloodstream—is emerging as a new modifiable risk factor. The findings carry profound implications for public health, clinical practice, and environmental policy. If MNPs act as pro-inflammatory or thrombogenic agents, they could join traditional risk factors like hypercholesterolemia and smoking in screening guidelines, potentially leading to blood-based MNP assays as biomarkers of exposure and risk. For biopharmaceutical developers, the association opens an uncharted therapeutic frontier: drugs that bind or accelerate clearance of circulating plastics, or interventions that block MNP-induced vascular inflammation. From a regulatory standpoint, the study injects a human health dimension into ongoing global plastics treaty negotiations, providing ammunition for stricter production caps and waste management mandates. The link with smoking and air pollution also reinforces the concept of the lung as a vulnerable portal for systemic contaminant exposure, suggesting that improving air quality and smoking cessation could indirectly reduce plastic particle absorption. While small and cross-sectional, the study lays a crucial foundation for longitudinal cohorts to establish temporality and dose-response relationships. Combined with earlier findings that MNPs accumulate in carotid plaques and predict adverse cerebrovascular outcomes, this research signals that plastic pollution may already be imposing a tangible cardiovascular burden. As global plastic production surpasses 400 million tons annually with minimal recycling, the cardiovascular toll could escalate in parallel, making this an urgent wake-up call for healthcare systems, industry, and policy makers alike.